MRK logo

Merck KGaA Stock Price

XTRA:MRK Community·€50.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 65 Fair Values set on narratives written by author

MRK Share Price Performance

€116.10
-40.85 (-26.03%)
39.2% undervalued intrinsic discount
€191.00
Fair Value
€116.10
-40.85 (-26.03%)
39.2% undervalued intrinsic discount
€191.00
Fair Value
Price €116.10
AnalystHighTarget €191.00
AnalystConsensusTarget €147.53
AnalystLowTarget €100.00

MRK Community Narratives

AnalystHighTarget·
Fair Value €191 37.1% undervalued intrinsic discount

Aging Populations And Digitalization Will Unlock Life Sciences Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value €147.53 18.6% undervalued intrinsic discount

Global Biotechnology And Digital Automation Will Drive Future Healthcare

0users have liked this narrative
0users have commented on this narrative
45users have followed this narrative
AnalystLowTarget·
Fair Value €105.5 13.8% overvalued intrinsic discount

Legacy Pharmaceutical And Chemical Businesses Will Decline As Regulations Tighten

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative

Recent MRK News & Updates

We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt

Jul 24
We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt

Merck KGaA's (ETR:MRK) Share Price Not Quite Adding Up

Jul 03
Merck KGaA's (ETR:MRK) Share Price Not Quite Adding Up

Merck KGaA (ETR:MRK) Will Pay A Dividend Of €2.20

Apr 25
Merck KGaA (ETR:MRK) Will Pay A Dividend Of €2.20

We Think Shareholders May Want To Consider A Review Of Merck KGaA's (ETR:MRK) CEO Compensation Package

Apr 19
We Think Shareholders May Want To Consider A Review Of Merck KGaA's (ETR:MRK) CEO Compensation Package

Merck KGaA Key Details

€21.2b

Revenue

€8.8b

Cost of Revenue

€12.5b

Gross Profit

€9.6b

Other Expenses

€2.9b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 13, 2025
Earnings per share (EPS)
6.58
Gross Margin
58.69%
Net Profit Margin
13.49%
Debt/Equity Ratio
30.9%

Merck KGaA Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet, undervalued and pays a dividend.

0 Risks
5 Rewards

About MRK

Founded
1668
Employees
63160
CEO
Belen Garijo Lopez
WebsiteView website
www.emdgroup.com

Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables, devices, instruments, software, and services for research, production, and testing; process solutions consisting of filtration devices, chromatography resins, single-use systems, process chemicals, and excipients; and life science services, such as monoclonal antibodies, high-potency active pharmaceutical ingredients, antibody-drug conjugates, and viral and gene therapy products, as well as contract development, manufacturing, and testing services. Its Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, cardiovascular, metabolism, and endocrinology disorders; and provides general medicines, injection devices, and disease monitoring software. The Electronics segment supplies materials comprising thin films, patterning and planarization formulations, specialty gases, optronics, and optical metrology equipment for the semiconductor and display industries, as well as provides delivery systems and services. It has in-licensing agreements with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

German Market Performance

  • 7 Days: -1.0%
  • 3 Months: -1.6%
  • 1 Year: 12.4%
  • Year to Date: 12.1%
Over the last 7 days, the market has dropped 1.0%, driven by losses in the Consumer Discretionary and Industrials sectors of 4.0% and 1.8%, respectively. In the last year, the market is actually up 12%. Looking forward, earnings are forecast to grow by 17% annually. Market details ›